Will OptiBiotix Health stock go up?

According to Danelfin AI, OptiBiotix Health has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (44.86%) is -4.73% vs. the average probability (49.60%) of all European stocks.

Is it a good time to buy, sell, or hold OptiBiotix Health stock right now?

OptiBiotix Health has today a Hold rating (AI Score 4/10), according to Danelfin AI. Its probability of beating the market in 3 months (44.86%) is -4.73% vs. the average probability (49.60%) of all European stocks, based on our AI-powered analysis. You can find more details on whether OptiBiotix Health stock is a good buy .

What is going on with OptiBiotix Health stock in the last 3 months?

The OptiBiotix Health stock performance in the last quarter has been -.

Does OptiBiotix Health offer dividend payments?

No, OptiBiotix Health does not currently pay dividends.

What is the current market capitalization of OptiBiotix Health?

OptiBiotix Health's market cap is GBX 6.61M, as of 2026-07-03 08:00.

OptiBiotix Health PLC (OPTI.L) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

OPTI.L AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score

Hold

OptiBiotix Health (OPTI.L) has an AI Score of 4/10 (Hold) because, according to an overall analysis, it has a probability advantage of -4.73% of beating the market (STOXX 600) in the next 3 months. This advantage is calculated as the difference between the average probability of any European stock (49.60%) and the probability of OPTI.L (44.86%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any European stock of beating the market (3M)49.60%
OPTI.L probability advantage of beating the market (3M)-4.73%
OPTI.L probability of beating the market (3M)44.86%

OPTI.L probability advantage of beating the market (3M): -4.73%

The AI-powered overall analysis of OptiBiotix Health (OPTI.L) is based on the 0 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 24 months (alpha signals). These alpha signals explain the probability advantage of OPTI.L:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
-	-	-	-	-

OPTI.L probability advantage of beating the market (3M)Total:-4.73%
OPTI.L AI Score

Significant changes Vs previous day

OPTI.L Trading Parameters

Trading parameters are unavailable for OPTI.L.

OPTI.L Frequently Asked Questions

Will OptiBiotix Health stock go up?
According to Danelfin AI, OptiBiotix Health has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (44.86%) is -4.73% vs. the average probability (49.60%) of all European stocks.
Is it a good time to buy, sell, or hold OptiBiotix Health stock right now?
What is going on with OptiBiotix Health stock in the last 3 months?
Does OptiBiotix Health offer dividend payments?
What is the current market capitalization of OptiBiotix Health?

OptiBiotix Health PLC Company Profile

OptiBiotix Health PLC (OPTI.L) develops and commercializes a range of scientifically proven, natural ingredients for the food, health, and pharmaceutical industries. The company focuses on harnessing the power of the human microbiome to create innovative health solutions. It applies advanced biotechnology to identify and develop specific microbial strains and their metabolites. These ingredients are designed to address significant global health challenges, offering natural alternatives for improving well-being.

The company's research and development efforts center on understanding the intricate relationship between the microbiome and human physiology. It employs a rigorous scientific process to screen, select, and optimize beneficial microorganisms and their compounds. This systematic approach leads to the creation of proprietary ingredients with targeted functional properties. These ingredients aim to improve metabolic health, manage weight, reduce cholesterol levels, and support immune system function. The company's platform enables the development of novel solutions for various chronic conditions.

OptiBiotix Health PLC offers a portfolio of branded ingredients for diverse applications across consumer health. LPLDL is a patented probiotic strain specifically developed for effective cholesterol reduction. SlimBiome is a functional ingredient blend designed to support healthy weight management by promoting satiety, reducing cravings, and balancing gut microbiota. SweetBiotix provides a low-calorie, gut-friendly sweet fiber alternative, suitable for sugar reduction in food products. These advanced ingredients are formulated for seamless integration into a wide array of foods, beverages, dietary supplements, and medical nutrition products.

The company primarily serves business-to-business customers, including manufacturers, formulators, and brand owners in the health, food, and pharmaceutical sectors. It also engages with research institutions for collaborative development and validation. OptiBiotix Health PLC distributes its ingredients and technologies through a combination of direct sales and a network of international partners. The company generates revenue through product sales, licensing agreements, and royalties, employing a go-to-market strategy that combines direct engagement with channel partners to achieve global market penetration.

Sector:
Country:United Kingdom

Pros

Proprietary intellectual property portfolio in microbiome science

Asset-light licensing model generating royalty streams

Expanding global market for gut health and weight management

Clinical validation of microbiome-modulating product efficacy

Broad pipeline of health-focused ingredient technologies

Cons

Evolving regulatory landscape for health claims and novel ingredients

Dependence on commercialization success of licensing partners

Substantial capital requirements for ongoing research and development

Intense competition from established health and nutrition companies

Uncertainty in consumer adoption of new microbiome technologies

Pros

Cons

Company

AI Score

Compare

SBTX.LSkinBioTherapeutics PLC

BIOG B.STBiogaia AB

BCX.WABioceltix SA

BIO.WABioton SA

ALVAL.PAValbiotis SA

Company

AI Score

Compare

OPTI.L Top 10 Industry Stocks

Biotechnology

	Company	AI Score	Compare
1	PHM.MCPharma Mar SA
2	BSLN.SWBasilea Pharmaceutica AG Allschwil
3	ARBS.MIArterra Bioscience SpA
4	ALERS.PAEurobio Scientific SA
5	KURN.SWKuros Biosciences AG
6	AZT.OLArcticzymes Technologies ASA
7	RDG.WARead Gene SA
8	BIOA B.STBioArctic AB
9	RTALB.E.ISRTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS
10	VITR.STVitrolife AB

	Company	AI Score	Compare

OPTI.L Top 10 Sector Stocks

Health Care

	Company	AI Score	Compare
1	FAE.MCFaes Farma SA
2	REC.MIRecordati Industria Chimica e Farmaceutica SpA
3	ALK B.COALK-Abello A/S
4	ANCR.LAnimalcare Group plc
5	MPARK.E.ISMLP Saglik Hizmetleri AS
6	PRM.MCPrim SA
7	DMP.DEDermapharm Holding SE
8	TRILC.E.ISTurk Ilac ve Serum Sanayi AS
9	TNZTP.E.ISTapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS
10	LKMNH.E.ISLokman Hekim Engurusag Saglik Turizm Egitim Hizmetleri ve Insaat Taahhut AS

	Company	AI Score	Compare

OPTI.L Stock AI Analysis